The cumulative success of three pivotal trials strengthens the likelihood of regulatory approval and commercialization. Traders should monitor upcoming data presentations and regulatory submissions, as tozorakimab could become a key growth driver in AstraZeneca's respiratory portfolio.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $200.56entry
- T+1 · 7mo ago −2.39%α −1.74% · $195.77
- T+5 · 7mo ago −6.62%α −7.53% · $187.29
- T+20 · 6mo ago −8.30%α −12.50% · $183.91
- T+60 · 4mo ago −17.98%α −24.06% · $164.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced positive high-level results from the Phase III MIRANDA trial, showing that tozorakimab significantly reduced moderate-to-severe COPD exacerbations. This marks the third successful pivotal trial for the drug, reinforcing its potential as a first-in-class IL-33-targeting biologic.
Key Facts
- Tozorakimab met the primary endpoint in the Phase III MIRANDA trial, demonstrating a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations.
- This is the third positive pivotal Phase III trial for tozorakimab, following prior successes in the OBERON and TITANIA trials.
- The MIRANDA trial evaluated a biweekly dosing regimen, expanding on previous monthly dosing data.
- Tozorakimab was generally well tolerated with a safety profile consistent with prior trials.
- The drug is being studied in additional indications, including severe viral lower respiratory tract disease and asthma.
Financial Impact
Potential for significant future revenue if approved, given COPD affects nearly 400 million people globally and current therapies fail to prevent exacerbations in over 50% of patients.
Risk Factors
- Regulatory approval is not guaranteed despite positive trial results.
- Competition from other biologics and emerging therapies in COPD could limit market penetration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003703 |
| Document: 0001654954-26-003703-index-headers.html | 0001654954-26-003703 |
| Document: 0001654954-26-003703-index.html | 0001654954-26-003703 |
| Document: 0001654954-26-003703.txt | 0001654954-26-003703 |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers